Skip to Main Content

2,036

Views

1

CrossRef citations to date

0

Altmetric

Articles

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Lynda Spelmana Veracity Clinical Research, Brisbane, AustraliaView further author information

,

Diana Rubelb Woden Dermatology, ACT, AustraliaView further author information

,

Alan Brnabicc Eli Lilly Australia Pty Limited, West Ryde, AustraliaView further author information

,

Nicole Burkhardtc Eli Lilly Australia Pty Limited, West Ryde, AustraliaView further author information

,

Elisabeth Riedld Eli Lilly Ges.m.b.H, Vienna, Austria;e Department of Dermatology, Medical University of Vienna, Vienna, AustriaView further author information

&

Peter Foleyf Skin Health Institute, Carlton, Australia;g The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, AustraliaCorrespondence[email protected]
View further author information